The half-life is the molecule

Every emerging medical technology eventually hits a binding constraint, and for targeted alpha therapy it is not biology, capital, or regulation. It is the 10.6-hour half-life of lead-212. Orano's ATLab Valenciennes is the first industrial plant whose floor plan, location, and shipping routes were engineered around a single atomic clock.

The shape of the facility is the shape of the constraint. Sited within two hours of Paris and Brussels airports, built for EUR 25 million (about USD 28 million) and sized to reach roughly 70% of Europe's population inside a single production-to-patient day, the lab exists to compress a window the isotope will not let expand. Orano Med's CEO Frederic Desdouits has called the design a logistics answer to a physical problem. Sister capacity under commissioning in Indianapolis extends the same pattern across the Atlantic, which is how a continent-scale supply chain gets assembled one half-life at a time.

The clinical pipeline, four candidates with partners including Sanofi, Roche, and Molecular Partners, is still early. The constraint, though, has shifted. Twenty years of research were gated by supply. ATLab is engineered to end that gate. The drug was never the slow part of the modality. The clock was.